William D. Nordhaus, PhD ’67, a scholar known for his work on the long-term interaction of climate change and the economy, will share the 2018 Nobel Prize in economic sciences with Paul M. Romer of New York University’s Stern School of Business, who also did graduate work at MIT. The Royal Swedish Academy of Sciences announced that the two economists have “significantly broadened the scope of economic analysis by constructing models that explain how the market economy interacts with nature and knowledge.”
In Nordhaus’s case, the academy cited his pioneering development of an “integrated assessment model” representing “the global interplay between the economy and the climate.” Nordhaus has refined multiple iterations of his model. He has also written about climate and economics for a broad audience as the author of several books.
Nordhaus, who is a professor of economics at Yale University, completed his PhD dissertation at MIT under the supervision of Robert M. Solow, himself the 1987 winner of the economics Nobel. Multiple winners of this award, including Peter Diamond, George Akerlof, and Joseph Stiglitz, have also had Solow as their principal advisor in MIT’s graduate program. Additionally, MIT biology professor H. Robert Horvitz ’68, a Nobel laureate in 2002 in the category of Physiology or Medicine, wrote his undergraduate thesis in economics under the direction of Solow.
Nordhaus is the 37th MIT alum to win a Nobel Prize and the 90th winner with a connection to MIT. Five people have won the economics Nobel while serving as members of the MIT faculty; another 11 MIT alumni, including Nordhaus, have won the prize, as have seven former MIT faculty members.
The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.
Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.
Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
The dark secret behind those cute AI-generated animal images
Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.